首页> 美国卫生研究院文献>ESMO Open >Evaluation of the use and efficacy of (neo)adjuvant chemotherapy in angiosarcoma: a multicentre study
【2h】

Evaluation of the use and efficacy of (neo)adjuvant chemotherapy in angiosarcoma: a multicentre study

机译:(Neo)佐剂化疗在昂贵arcoma中的使用和疗效评估:多期面研究

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Angiosarcomas constitute approximately 2% to 3% of all soft tissue sarcomas, are characterised by an aggressive clinical behaviour and poor outcome. Optimal management of localised angiosarcomas consists of complete surgical resection with or without radiation. However, due to the infiltrating nature of this disease, complete resection is often not possible. Despite optimal management, the outcome of patients with localised disease remains poor. The role of (neo)adjuvant chemotherapy in angiosarcomas remains undefined. The aim of this study is to document the outcome of patients treated with (neo)adjuvant chemotherapy and assess the feasibility of performing a prospective trial by evaluating the number of patients treated at sarcoma referral centres.
机译:Agiosarcomas占所有软组织肉瘤的约2%至3%,其特征在于激进的临床行为和差的结果。局部高管的最佳管理由具有或无辐射的完全手术切除组成。然而,由于这种疾病的浸润性质,通常不可能完全切除。尽管管理层,但局部疾病患者的结果仍然差。 (Neo)佐剂化疗在服从中的作用仍然是未定义的。本研究的目的是记录用(Neo)佐剂化疗治疗的患者的结果,并评估通过评估在Sarcoma推荐中心治疗的患者数量进行前瞻性试验的可行性。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号